DiscGenics is a privately funded biotechnology company focused on developing advanced spinal therapeutics to treat patients with intervertebral disc diseases. It is currently developing IDCT, an off-the-shelf injectable therapeutic.
The issuance of the patent abroad extends the protection of the company’s domestic intellectual property into major international markets.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
